US Opens Zero-Tariff Route for Select Speciality Medicines from India
Bharatmorning.com – India has been included in a US decision to apply a zero ad valorem tariff to certain specialised medicines and pharmaceutical inputs used in the treatment of rare and complex conditions. The measure covers imports from 20 jurisdictions and comes as Washington moves toward much steeper duties on other patented drug products.
The exemption applies to a defined group of pharmaceutical articles rather than to all medicines imported from the participating countries. Eligible categories include treatments for rare diseases, infertility medicines, cell therapies, gene therapies, antibody-drug conjugates, and veterinary pharmaceuticals. Ingredients and components used to make those products can also receive the zero-duty treatment.
An ad valorem tariff is charged as a percentage of an imported product’s declared value. Setting that rate at zero means qualifying shipments in the listed categories will not face that particular import duty.
India among 20 eligible trading partners
The US Commerce Department published the eligible-country list in the Federal Register while implementing President Donald Trump’s plan to alter tariffs on pharmaceutical imports. India is joined by Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, Britain and Vietnam.
The notice links the preferential tariff treatment to countries that have an existing trade and security framework agreement with the United States or are expected to have one. For Indian manufacturers supplying specialised therapies or the materials needed to produce them, the distinction may be important as US tariff policy becomes more selective across pharmaceutical supply chains.
The zero-tariff measure does not remove duties from every type of pharmaceutical import. Instead, it creates a narrower channel for products tied to medical needs where manufacturing, research, and supply arrangements can be particularly specialised. Cell and gene therapies, for example, often involve highly specific production processes and components, while antibody-drug conjugates combine antibodies with active therapeutic agents for targeted treatment approaches.
Higher duties still scheduled for specified patented products
The exemptions are being introduced alongside a broader Section 232 tariff programme covering certain patented pharmaceuticals, biologics and associated ingredients entering the US. Trump’s April proclamation adjusted pharmaceutical imports under Section 232 of the Trade Expansion Act, a provision used to address imports on national-security grounds.
Under that plan, specified patented pharmaceutical products and related ingredients face a 100 per cent tariff. The charge took effect on July 31 for companies identified in one annex. It is scheduled to extend to other covered companies on September 29.
The new country-based exemption therefore draws a clear dividing line: some speciality medicines and their inputs from eligible partners can enter at a zero tariff rate, while designated patented products outside the exemption remain subject to substantially higher duties.
Generic medicines and their associated ingredients are outside the Section 232 pharmaceutical tariff programme. This is a significant distinction because generic products are generally sold after patent protection has expired and are commonly used to provide lower-cost alternatives to branded medicines.
Technical changes clarify what is covered
The Commerce Department notice also corrects and clarifies elements of the original proclamation. One revision updates the definition of “generic pharmaceutical articles” so that unpatented animal-health products are expressly included.
Another clarification narrows the meaning of “pharmaceutical articles.” The term covers finished pharmaceutical products, their active pharmaceutical ingredients, and the key starting materials used in producing those ingredients. By defining the scope more precisely, the notice helps distinguish the covered medicines and inputs from broader categories of chemical or medical goods.
These details matter for exporters, importers and manufacturers because tariff treatment may depend not only on where a product is shipped from, but also on its patent status, therapeutic category, stage of production and the nature of the ingredients involved. A finished medicine, an active ingredient and an early-stage material may each be assessed differently under the programme.
What the decision means for pharmaceutical trade
The US action reflects an effort to encourage domestic pharmaceutical production while retaining limited access to selected medicines and inputs from approved trade partners. For patients and healthcare providers, the carve-out is especially relevant to therapies designed for rare diseases and other specialised uses, where supply options may be more limited than for widely available medicines.
For India, inclusion on the eligible list provides an opening for qualifying speciality pharmaceutical exports to reach the US without the new ad valorem duty. The benefit is not automatic for all drug shipments: businesses will need to determine whether a product falls within an exempt category and meets the applicable country and trade-framework conditions.
The policy also underlines the difference between the US approach to generics and its treatment of certain patented medicines. Generics remain excluded from the Section 232 duties, while a separate exemption protects qualifying speciality therapies and components from eligible countries. At the same time, the 100 per cent tariff remains in place for the patented products specifically covered by the proclamation.
As the September 29 deadline approaches for additional covered companies, pharmaceutical firms will be watching how the exemption criteria are applied in practice. The Federal Register notice offers a more detailed framework for determining which specialised medicines, ingredients and animal-health products can qualify for zero tariff treatment under the revised US rules.
Related Reading
Frequently Asked Questions
What is US sets zero tariff on certain?
US sets zero tariff on certain is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does US sets zero tariff on certain matter?
US sets zero tariff on certain matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.